Prestige Consumer Healthcare Inc.

PBH • Medical - Distribution

$49.36

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL FAVORABLEAtractivaConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$2.35B

Crecimiento

18.1%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 17.5%Flujo de caja libre positivo · 5.25Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 15.09Nivel de deuda manejable · 0.55

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 12:56 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$49.36

Change0.00%

Shares Out47.60M

Market Cap$2.35B

Enterprise Value$2.32B

52W Range42.62 - 72.89

Beta0.35

P/E13.66

P/S2.13

P/B1.23

P/FCF9.66

EV/Sales2.10

Price$49.36

Change0.00%

Shares Out47.60M

Market Cap$2.35B

Enterprise Value$2.32B

52W Range42.62 - 72.89

Beta0.35

P/E13.66

P/S2.13

P/B1.23

P/FCF9.66

EV/Sales2.10

EV/EBITDA7.50

EV/FCF9.53

Earnings Yield7.32%

FCF Yield10.35%

Dividend Yield0.00%

Gross Margin52.78%

Oper. Margin28.42%

Profit Margin17.48%

Debt/Eq0.55

Current Ratio3.57

Quick Ratio2.25

Revenue 5Y18.09%

FCF 5Y18.19%

Target$81.67

Target Upside65.46%

Target Median$86.00

Target Range66.00 - 93.00

Volume721.24K

Avg Volume695.11K

EPS Surprise-0.16

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

84/100

Fortaleza financiera

Deuda, caja, estabilidad

87/100

Potencial de crecimiento

Ingresos y expansión

37/100

Atractivo del precio

Barata o cara hoy

83/100

Por qué este puntaje▼

Márgenes estables o en mejora · 17.5%Flujo de caja libre positivo · 5.25Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 15.09Nivel de deuda manejable · 0.55Liquidez saludable · 3.57

Analyst view

Analyst sentiment and price target

PBH

Analyst sentiment

Based on 17 analyst votes · 2026-10-20

76/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$66.00

Promedio

$81.67

Mediana

$86.00

Alto

$93.00

Resumen de la compañía

IPO: 2/10/2005

Industria: Medical - Distribution

P/B i: 1.23

Deuda / Patrimonio i: 0.55

Margen operativo: 28.42%

Margen neto: 17.48%

ROE i: -

ROIC: -

Salud financiera

Puntaje17 / 20

Deuda / Patrimonio: 0.55

Ratio corriente: 3.57

Ratio rápido: 2.25

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

BYOM JOHN E

Transacción: 08/04/2026

COMPRA

Cambio

+2,981

Precio

Not reported

Presentación

08/05/2026

Tipo

COMPRA

Clark Celeste A.

Transacción: 08/04/2026

COMPRA

Cambio

+2,981

Precio

Not reported

Presentación

08/05/2026

Tipo

COMPRA

DArecca James

Transacción: 08/04/2026

COMPRA

Cambio

+2,981

Precio

Not reported

Presentación

08/05/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
BYOM JOHN E	COMPRA	+2,981	Not reported	08/04/2026	08/05/2026
Clark Celeste A.	COMPRA	+2,981	Not reported	08/04/2026	08/05/2026
DArecca James	COMPRA	+2,981	Not reported	08/04/2026	08/05/2026
Kelly John F.	COMPRA	+2,981	Not reported	08/04/2026	08/05/2026
ZIER DAWN M.	COMPRA	+2,981	Not reported	08/04/2026	08/05/2026
Sacco Christine	VENTA	-1,091	$55.09	05/02/2026	05/14/2026
Zerillo Jeffrey	VENTA	-351	$52.28	05/11/2026	05/12/2026
Mekhail Adel	VENTA	-487	$54.59	05/07/2026	05/11/2026
Lombardi Ronald M.	VENTA	-2,543	$54.59	05/07/2026	05/11/2026
Sacco Christine	VENTA	-991	$54.59	05/07/2026	05/11/2026
Zerillo Jeffrey	VENTA	-305	$54.36	05/07/2026	05/11/2026
Lombardi Ronald M.	VENTA	-2,197	$55.75	05/05/2026	05/07/2026
Sacco Christine	VENTA	-1,267	$55.75	05/05/2026	05/07/2026
Zerillo Jeffrey	VENTA	-1,207	$54.99	05/05/2026	05/07/2026
Zerillo Jeffrey	VENTA	-346	$55.32	05/05/2026	05/06/2026
Lombardi Ronald M.	VENTA	-16,789	$55.31	05/04/2026	05/06/2026
Mekhail Adel	VENTA	-1,695	$55.31	05/04/2026	05/06/2026
Zerillo Jeffrey	VENTA	-1,243	$55.31	05/04/2026	05/06/2026
P'Pool William	VENTA	-1,888	$55.31	05/04/2026	05/06/2026
Sacco Christine	VENTA	-3,434	$55.31	05/04/2026	05/06/2026

Sobre la compañía

Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.

Fuente - Link

Competidores

ATEC CON CPRX HTFL ICUI IRON LEGN LIVN PRVA ZLAB

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?

PBH's brand-building, acquisitions and e-commerce growth support fiscal 2027 revenue gains, but competition and currency risks remain key challenges.

Zacks Investment Research

Prestige Consumer Healthcare to Release Fiscal 2027 Second Quarter Earnings Results

TARRYTOWN, N.Y., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2027 second quarter and first half earnings release on Thursday, November 5, 2026 before the opening of the market.

GlobeNewsWire

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.

MarketBeat

Best Value Stocks to Buy for October 1st

BP and PBH made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 1, 2026.

Zacks Investment Research

PBH vs. NEOG: Which Stock Is the Better Value Option?

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	1.39	1.23	-0.16
2026-02-05	1.16	1.14	-0.02
2025-11-06	0.97	1.07	0.1
2025-08-07	1.01	0.95	-0.06
2025-05-08	1.3	1.32	0.02
2025-02-06	1.16	1.22	0.06
2024-11-07	1.08	1.09	0.01
2024-08-08	0.86	0.9	0.04
2024-05-14	1.14	0.98	-0.16
2024-02-08	1.04	1.06	0.02
2023-11-02	1.07	1.07	0
2023-08-03	1.01	1.06	0.05